This week: New studies of PCSK9 inhibitors for lipid lowering and a randomized controlled trial of early peanut exposure to prevent allergy Fahad and Amol want you to understand the following: 1. PCSK9 inhibitors are new cholesterol-lowering monoclonal antibodies that have been shown to reduce LDL beyond standard therapy with statins and have been associated with reduced ...
The post Peanut Placebo, Nocebo, PCSK9: Lipid lowering and peanut allergy appeared first on Healthy Debate.
